JPWO2020149395A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020149395A5
JPWO2020149395A5 JP2020566497A JP2020566497A JPWO2020149395A5 JP WO2020149395 A5 JPWO2020149395 A5 JP WO2020149395A5 JP 2020566497 A JP2020566497 A JP 2020566497A JP 2020566497 A JP2020566497 A JP 2020566497A JP WO2020149395 A5 JPWO2020149395 A5 JP WO2020149395A5
Authority
JP
Japan
Prior art keywords
cells
composition
acid sequence
mesenchymal stem
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020566497A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020149395A1 (ja
JP7536296B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2020/001433 external-priority patent/WO2020149395A1/ja
Publication of JPWO2020149395A1 publication Critical patent/JPWO2020149395A1/ja
Publication of JPWO2020149395A5 publication Critical patent/JPWO2020149395A5/ja
Priority to JP2024124327A priority Critical patent/JP7833204B2/ja
Application granted granted Critical
Publication of JP7536296B2 publication Critical patent/JP7536296B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020566497A 2019-01-18 2020-01-17 栄養障害型表皮水疱症治療薬 Active JP7536296B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024124327A JP7833204B2 (ja) 2019-01-18 2024-07-31 栄養障害型表皮水疱症治療薬

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019007201 2019-01-18
JP2019007201 2019-01-18
PCT/JP2020/001433 WO2020149395A1 (ja) 2019-01-18 2020-01-17 栄養障害型表皮水疱症治療薬

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024124327A Division JP7833204B2 (ja) 2019-01-18 2024-07-31 栄養障害型表皮水疱症治療薬

Publications (3)

Publication Number Publication Date
JPWO2020149395A1 JPWO2020149395A1 (ja) 2021-11-25
JPWO2020149395A5 true JPWO2020149395A5 (https=) 2023-01-26
JP7536296B2 JP7536296B2 (ja) 2024-08-20

Family

ID=71613343

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566497A Active JP7536296B2 (ja) 2019-01-18 2020-01-17 栄養障害型表皮水疱症治療薬
JP2024124327A Active JP7833204B2 (ja) 2019-01-18 2024-07-31 栄養障害型表皮水疱症治療薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024124327A Active JP7833204B2 (ja) 2019-01-18 2024-07-31 栄養障害型表皮水疱症治療薬

Country Status (7)

Country Link
US (1) US20220088083A1 (https=)
EP (1) EP3912644A4 (https=)
JP (2) JP7536296B2 (https=)
KR (1) KR20210116531A (https=)
CN (1) CN113646006A (https=)
AU (1) AU2020209687A1 (https=)
WO (1) WO2020149395A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020459825A1 (en) * 2020-07-22 2023-03-16 Osaka University Therapeutic agent for dystrophic epidermolysis bullosa
JP2025094280A (ja) * 2022-01-21 2025-06-25 国立大学法人大阪大学 細胞シート
CN116555349A (zh) * 2023-01-09 2023-08-08 中吉智药(南京)生物技术有限公司 一种腺相关病毒载体及其构建方法与应用
CN118001404B (zh) * 2024-02-06 2025-02-25 四川大学华西医院 抑制C17orf67基因表达试剂在制备治疗获得性大疱表皮松解症药物中的用途
KR102736437B1 (ko) * 2024-06-20 2024-12-02 주식회사 에이바이오테크 콜라겐 합성 촉진 활성을 갖는 콜라겐 타입 7 저분자 펩타이드 및 이를 이용한 방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2720903C (en) * 2008-04-14 2019-01-15 Sangamo Biosciences, Inc. Linear donor constructs for targeted integration
AU2013259647B2 (en) * 2012-05-07 2018-11-08 Corteva Agriscience Llc Methods and compositions for nuclease-mediated targeted integration of transgenes
US12558316B2 (en) * 2013-03-13 2026-02-24 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
CN105683376A (zh) * 2013-05-15 2016-06-15 桑格摩生物科学股份有限公司 用于治疗遗传病状的方法和组合物
WO2017035416A2 (en) * 2015-08-25 2017-03-02 Duke University Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
JP7159048B2 (ja) 2016-01-04 2022-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 遺伝子修正自己ケラチノサイトを使用する劣性栄養障害型表皮水疱症のための遺伝子療法
KR20180118795A (ko) * 2016-03-18 2018-10-31 인트렉손 코포레이션 Vii형 콜라겐 결핍증의 치료를 위한 조성물 및 방법
RS60410B1 (sr) * 2016-04-08 2020-07-31 Krystal Biotech Inc Kompozicije za upotrebu u metodama za tretman rana, poremećaja i bolesti kože
WO2018007871A1 (en) * 2016-07-08 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of transthyretin amyloidosis
US10648002B2 (en) * 2016-11-22 2020-05-12 Regents Of The University Of Minnesota Method for correcting a genetic sequence
WO2018154413A1 (en) * 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of dystrophic epidermolysis bullosa (deb) and other collagen type vii alpha 1 chain (col7a1) gene related conditions or disorders
US20200038486A1 (en) * 2017-04-07 2020-02-06 StemRIM Inc. Therapeutic medicine for fibrous disease
ES3017696T3 (en) * 2017-05-17 2025-05-13 Bpgbio Inc Use of coenzyme q10 formulations in the treatment and prevention of epidermolysis bullosa
WO2018235834A1 (ja) * 2017-06-19 2018-12-27 国立大学法人北海道大学 表皮水疱症の治療剤
JP2019007201A (ja) 2017-06-23 2019-01-17 システム計測株式会社 免震構造
CN107904208B (zh) * 2017-12-25 2019-11-01 云舟生物科技（广州）有限公司 细胞表型研究用的细胞克隆及其筛选方法和应用
AU2019261438B2 (en) * 2018-04-27 2024-08-22 Seattle Children's Hospital (dba Seattle Children's Research Institute) Expression of FOXP3 in edited CD34+ cells
JP2022532078A (ja) * 2019-05-08 2022-07-13 アストラゼネカ アクチボラグ 皮膚及び創傷のための組成物並びにその使用の方法

Similar Documents

Publication Publication Date Title
JPWO2020149395A5 (https=)
JP2012518420A5 (https=)
JP2019524150A5 (https=)
JP2005533481A5 (https=)
FI3352776T3 (fi) Htt-repressoreita ja niiden käyttötapoja
JP2023540493A5 (https=)
JP2018521630A5 (https=)
JP2021521855A5 (https=)
JP2024535672A5 (https=)
CL2018000537A1 (es) Anticuerpo anti-factor d del complemento; polinucleótido codificante; vector que comprende dicho polinucleótido; célula húesped que comprende dicho vector; método de fabricación de anticuerpo; composición farmacéutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares (divisional de cl 1001-2009).
JP2025183226A5 (https=)
CN106978415B (zh) 转运rna片段及其应用
MX2020012332A (es) Casetes de expresion de alfa-glucosidasa de acido optimizado con codon y metodos de uso del mismo.
MX2019015502A (es) L-asparaginasa modificada.
RU2022103641A (ru) Искусственная модификация генома для регуляции экспрессии гена
RU2017127367A (ru) Белок, ассоциированный с устойчивостью к болезни, и кодирующий его ген и их применение в регулировании устойчивости растений к болезни
AR065281A1 (es) Proteinas de tipo trehalasa par el control de nematodos y metodos para su uso en plantas
RU2009140759A (ru) Бис-met-гистоны
JP2018533970A5 (https=)
RU2016105639A (ru) Гены, обеспечивающие устойчивость подсолнечника к ложной мучнистой росе
JP2016518838A5 (https=)
MX2022011806A (es) Vectores de adn no virales y usos de estos para expresar agentes terapéuticos contra gaucher.
JP2020513810A5 (https=)
JP2013531491A5 (https=)
JP2021514820A5 (https=)